The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.

Precisio Biotix董事长兼首席执行官马克·恩格尔（Mark Engel）的声明突显了Precisio Biotix在推进新型精密生物抗菌药物方面迈出的又一步。

DOVER, Del., March 14, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ('Precisio') today announced it has entered into an agreement with Mayo Clinic. The collaboration will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections..

多佛，Del。，2024年3月14日/PRNewswire/--Precisio Biotix Therapeutics（“Precisio”）今天宣布，它已经与梅奥诊所达成协议。该合作将包括共同开发针对易受抗微生物（AMR）感染适应症的新型精密抗菌药物。。

Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections. The Company's key assets include: (1) LysiThru™, the Company's industry-leading high throughput screening, engineering, and AI system for creating best- or first-in-class novel lysins (engineered precision enzymes that rapidly break targeted bacterial cell walls without causing resistance); (2) a strong pipeline of lysin and phage products that will be able to address multiple problematic bacterial diseases, including AMR infections; and (3) one of the strongest scientific teams to address the global need for novel medicines to fight AMR infections.

Precisio生产成本较低的新型精密生物抗菌剂，重点关注肺部和皮肤感染。该公司的关键资产包括：（1）LysiThru™是该公司业界领先的高通量筛选，工程和人工智能系统，用于创建最佳或一流的新型赖氨酸（工程精密酶，可快速破坏目标细菌细胞壁而不产生抗药性）；（2） 强大的赖氨酸和噬菌体产品管道，将能够解决多种有问题的细菌疾病，包括AMR感染；（3）是解决全球对抗AMR感染新药需求的最强科学团队之一。

.

.

Mayo Clinic has assets and know-how that complement Precisio's lysins. Dr. Assaf Raz, VP of R&D, stated: 'We are delighted to work with Mayo Clinic. We see this collaboration as an opportunity for validation of our technology.  We believe that when combined with Mayo Clinic's expertise, our precision biological antibacterials will be even more effective.

梅奥诊所拥有补充Precisio赖氨酸的资产和专有技术。研发副总裁阿萨夫·拉兹博士表示：“我们很高兴与梅奥诊所合作。我们将此次合作视为验证我们技术的机会。我们相信，当与梅奥诊所的专业知识相结合时，我们的精密生物抗菌剂将更加有效。

Together we will be addressing some of the largest bacterial disease problems, particularly antibiotic resistance.'.

我们将共同解决一些最大的细菌疾病问题，特别是抗生素耐药性。”。

Precisio's Chairman Mark Engel added 'Developing novel antibacterials is a very difficult business. We are working with lysins, since they attack pathogen cell walls, a mode of action that does not lead to antibiotic resistance. Lysins are one of the most powerful potential new modalities for treating AMR infections.

Precisio的董事长马克·恩格尔补充道：“开发新型抗菌药物是一项非常困难的工作。我们正在研究赖氨酸，因为它们会攻击病原体细胞壁，这种作用方式不会导致抗生素耐药性。赖氨酸是治疗AMR感染的最强大的潜在新方式之一。

Lysins are enzymes that specifically target and rapidly break down the cell walls of bacteria without creating new resistance and therefore can be used as alternatives to traditional antibiotics, particularly where these no longer work well against specific antibiotic-resistant infections.'.

赖氨酸是一种特异性靶向并迅速分解细菌细胞壁而不产生新耐药性的酶，因此可以用作传统抗生素的替代品，特别是在这些抗生素不再能很好地抵抗特定的抗生素耐药性感染的情况下。”。

Dr. Raymond Schuch, VP, Director of US Operations further added 'Antibiotic resistance is one of the world's great health challenges. And this collaboration may result in patients having faster access to novel therapeutics.'

美国运营部副总裁雷蒙德·舒奇博士进一步补充道，“抗生素耐药性是世界上最大的健康挑战之一。这种合作可能会使患者更快地获得新的治疗方法。”

Precisio is represented by Corporate Partners, a New York-based merchant bank. Partner Mario Gobbo said, 'Precisio is a unique organization and we are pleased to be working with management who have built several successful life science companies.  Precisio thus far has been funded by family capital: they are highly capital efficient and derisk their R&D whenever possible.'  .

Precisio由总部位于纽约的商业银行Corporate Partners代表。合伙人马里奥·戈博（MarioGobbo）说，“Precisio是一个独特的组织，我们很高兴与管理层合作，他们已经建立了几家成功的生命科学公司。到目前为止，Precisio的资金来自家族资本：他们的资本效率很高，尽可能嘲笑他们的研发。”。

Mayo Clinic has a financial interest in the technology and will use any revenue it receives to support its patient care, education and research.

梅奥诊所对这项技术有经济利益，并将使用其获得的任何收入来支持其患者护理、教育和研究。

ABOUT PRECISIO BIOTIX THERAPEUTICSPrecisio is a clinical-stage biotech company creating lower-cost novel precision engineered biological antibacterials, with an initial focus on skin and lung infections. Precisio is a platform-plus-product company (Rx, consumer). Management has had multiple previous successful exits..

关于PRECISIO BIOTIX Therapeutics PRECISIO是一家临床阶段的生物技术公司，创建低成本的新型精密工程生物抗菌药物，最初专注于皮肤和肺部感染。Precisio是一家平台加产品公司（Rx，消费者）。管理层之前曾多次成功退出。。

Contacts: Aileen Shen, Director of Investor Relations, at shencj@precisiobiotix.com or Daniela Wambold, Corporate Partners, dwambold@corporatepartners.com

联系人：投资者关系总监Aileen Shenshencj@precisiobiotix.com或Daniela Wambold，企业合伙人，dwambold@corporatepartners.com

SOURCE Precisio Biotix Therapeutics, Inc.

来源Precisio Biotix Therapeutics，Inc。